[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sirius Therapeutics Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":111},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,67,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100635797","phase-1-a-study-of-srsd384-in-overweight-or-obese-participants-100635797",false,"NCT07557355","A Study of SRSD384 in Overweight or Obese Participants","A Phase 1\u002F2a, Randomized, Double Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SRSD384 in Overweight or Obese Participants","Inclusion Criteria:\n\n* Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions;\n* Males or females;\n* Body mass index (BMI) between 27.0 and 40.0 kg\u002Fm2, inclusive;\n* Male subjects are not allowed to donate sperm, and female subjects are not allowed to donate eggs from the time the ICF is signed until at least 3 months after the last follow-up.\n\nExclusion Criteria:\n\n* Obesity attributable, in the investigator's opinion, to medication use, endocrinologic or monogenic disorders;\n* Having a significant medical history or clinical manifestations related to any allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine (other than overweight or obesity), or psychiatric conditions that are severe or unstable (determined by the investigator or medically qualified designee);\n* Evidence of active cancer within 2 years prior to screening (non-melanoma skin cancer, localized prostate cancer treated with curative intent, or other in situ carcinoma that does not require systemic therapy and is considered cured for at least 1 year is allowed);\n* Acute febrile illness within 7 days prior to randomization or evidence of active infection\n* Any major surgery within 3 months prior to screening or plan to have any major surgery during the study;\n* History of clinically significant hypersensitivity, intolerance, or allergy to any oligonucleotide or GalNAc as determined by the investigator;\n* Receipt of an investigational drug within 30 days or 5 half-lives of that drug, whichever is longer, prior to dose administration in this study;\n* Have previously completed or withdrawn from this study or any other study investigating SRSD384 and have previously received SRSD384.",true,"ALL","18 Years","70 Years",{"count":21,"type":22},78,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD384 alone in overweight or obese participants (Part A) and in combination with tirzepatide in overweight or obese participants with T2DM (Part B).",[29],"Overweight , Obesity","NOT_YET_RECRUITING","2026-06-03",{"date":33,"type":34},"2026-06-05","ACTUAL",{"date":36,"type":22},"2026-06",{"date":38,"type":22},"2027-10",{"name":40,"class":41},"Sirius Therapeutics Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":42},"100617402","phase-2-a-study-of-srsd107-in-participants-with-chronic-coronary-andor-peripheral-arterial-disease-100617402","NCT07318155","A Study of SRSD107 in Participants With Chronic Coronary and\u002For Peripheral Arterial Disease","A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of Subcutaneously Administered SRSD107 in Participants With Chronic Coronary and\u002For Peripheral Arterial Disease","Inclusion Criteria:\n\n* Able to comprehend and willing to sign an ICF and to abide by the study restrictions.\n* Males or females aged 18 to 75 years, inclusive.\n* Body mass index (BMI) between 18.0 and 35.0 kg\u002Fm2, inclusive.\n* History of chronic coronary and\u002For peripheral arterial disease\n\nExclusion Criteria:\n\n* Known bleeding disorder\n* Severe heart failure with known left ventricular ejection fraction \\\u003C35%, or New York Heart Association (NYHA) class III or IV symptoms.\n* Genetic cardiomyopathies or other non-ischemic cardiomyopathies that are not related to atherosclerotic cardiovascular disease.\n* History of ethanol abuse or addictive drug use (cannabis products allowed) within 6 months of screening.\n* Receipt of an investigational drug (IP) within 30 days or 5 half-lives of that drug, whichever is longer, prior to dose administration in this study.\n* Previous use of SRSD107.","75 Years",{"count":52,"type":22},104,[26],"The study is a Phase 2a, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the pharmacodynamics (PD), safety and pharmacokinetics (PK) of multiple doses of SRSD107 in participants with coronary arterial disease (CAD) and\u002For peripheral arterial disease (PAD) with aspirin as background concomitant therapy.",[56,57],"Coronary Artery Disease (CAD)","Peripheral Arterial Disease","RECRUITING","2026-04-23",{"date":61,"type":34},"2026-04-29",{"date":63,"type":34},"2025-03-11",{"date":65,"type":22},"2028-12",{"name":40,"class":41},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":42},"100603746","phase-2-a-study-to-compare-the-efficacy-and-safety-of-srsd107-and-enoxaparin-in-adult-subjects-undergoing-tka-100603746","NCT07140523","A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA","A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Active Controlled Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing Elective Primary Unilateral Total Knee Arthroplasty","Inclusion Criteria:\n\n1. Able to provide written informed consent before any study assessment is performed.\n2. Male and female subjects, of any race, between 60 and 80 years of age, inclusive.\n3. Body mass index between 18.0 and 35.0 kg\u002Fm2, inclusive.\n4. Eligible to undergo elective primary unilateral TKA under general anesthesia.\n5. Willing to comply with study requirements including taking study drug at least 28 days prior to TKA, clinic visits, and venography at 10-14 days post TKA.\n6. aPTT, PT, and INR within the normal reference range at screening.\n\nExclusion Criteria:\n\n1. Active bleeding requiring medical or surgical intervention within 4 weeks prior to screening.\n2. Known bleeding disorder; history of increased bleeding tendency or any other condition that in the opinion of the investigator contraindicates prophylactic anticoagulation.\n3. History of intracranial, intraspinal, or intraocular bleeding.\n4. Evidence of active cancer, or a history of malignancy, within 2 years prior to screening.\n5. Myocardial infarction, DVT, PE, stroke , transient ischemic attack, systemic embolism, valvular thrombosis, or splanchnic thrombosis in the 6 months prior to screening.\n6. Uncontrolled blood pressure at the time of screening.\n7. Estimated glomerular filtration rate (eGFR) \\\u003C 45 mL\u002Fmin\u002F1.73m2.\n8. Liver dysfunction, liver cirrhosis, history of hepatic encephalopathy, esophageal varices, or portocaval shunt.\n9. Clinically significant anemia at screening.\n10. Platelet counts \\\u003C100,000\u002Fm3 at screening or a history of heparin-induced thrombocytopenia.\n11. Positive test for human immunodeficiency virus (HIV) , positive hepatitis B surface antigen, and\u002For active hepatitis C at screening.\n12. Ongoing or anticipated need for anticoagulation or antiplatelet therapy from 7 days prior to surgery through the EoS visit.\n13. Participation in an interventional clinical study within 5 half-lives of the investigational drug or 30 days prior to screening, whichever is longer.\n14. Use of any ASO or siRNA products within 1 year prior to screening. Diet and Lifestyle.\n15. Recent or current history of alcoholism or recreational drug abuse.\n16. History of hypersensitivity to any of the study drugs or its excipients, to drugs of similar chemical classes or drugs issued from the same biologic origin or any contraindication listed in the label for enoxaparin.\n17. Unable to undergo venography due to a known allergy to the contrast agent, anticipated poor venous access, impaired renal function, or any other reason identified and specified by the investigator.\n18. Anticipated elective surgery during the study period.\n19. Any other condition or circumstance that would affect the subject's ability to be compliant with study drug administration or study procedures, in the opinion of the investigator.","60 Years","80 Years",{"count":77,"type":22},450,[26],"This is a Phase 2, multicenter, randomized, open-label, parallel group, blinded endpoint evaluation, active-controlled, dose-finding study.This study is designed to compare the efficacy and safety of 3 dose levels of SRSD107 and enoxaparin 40 mg daily in subjects undergoing elective primary unilateral TKA.",[81],"Venous Thromboembolism","2026-01-13",{"date":84,"type":34},"2026-01-15",{"date":86,"type":34},"2025-09-16",{"date":88,"type":22},"2026-10-31",{"name":40,"class":41},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":42},"100606214","phase-1-a-study-of-srsd216-in-patients-with-elevated-lipoprotein-a-100606214","NCT07172646","A Study of SRSD216 in Patients With Elevated Lipoprotein (a)","A Phase I\u002FII, Randomized, Double Blind, Placebo Controlled, Dose-Escalation and -Expansion Study to Evaluate the Safety, Tolerability, PK, and PD of Subcutaneously Administered SRSD216 in Patients With Elevated Lipoprotein(a)","Inclusion Criteria:\n\n* Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions;\n* Males or females, of any race;\n* Body mass index (BMI) between 18.0 and 40.0 kg\u002Fm2, inclusive;\n* Male subjects are not allowed to donate sperm, and female subjects are not allowed to donate eggs from the time the ICF is signed until at least 3 months after the last follow-up.\n\nExclusion Criteria:\n\n* Any history or evidence of abnormal bleeding or coagulopathy; or evidence of prolonged or unexplained, clinically significant bleeding, or frequent unexplained bruising or thrombosis; or history of spontaneous bleeding;\n* Evidence of active or suspected cancer within 3 years prior to screening (non-melanoma skin cancer, localized prostate cancer treated with curative intent, or other in situ carcinoma that does not require systemic therapy and is considered cured for at least 1 years is allowed);\n* Acute febrile illness within 7 days prior to dose administration or evidence of active infection;\n* Any major surgery within 3 months prior to screening or plan to have any major surgery during the study;\n* History of clinically significant hypersensitivity, intolerance, or allergy to any oligonucleotide or GalNAc as determined by the investigator;\n* Fasting TG≥ 500 mg\u002FdL (5.6 mmol\u002FL) during screening;\n* Receipt of an investigational drug within 30 days or 5 half-lives of that drug, whichever is longer, prior to dose administration in this study;\n* Have previously completed or withdrawn from this study or any other study investigating SRSD216 and have previously received SRSD216.",{"count":98,"type":22},84,[25,26],"This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD216 and to identify a dose range for further studies in subjects with elevated Lp(a) level with or without ASCVD history.",[102],"Hyperlipoproteinemia (a)","2026-01-03",{"date":105,"type":34},"2026-01-06",{"date":107,"type":34},"2025-04-07",{"date":109,"type":22},"2027-04",{"name":40,"class":41},""]